Perspectives in Lipocalin-2: Emerging Biomarker for Medical Diagnosis and Prognosis for Alzheimer's Disease
- Author:
Juhyun SONG
1
;
Oh Yoen KIM
Author Information
- Publication Type:Review
- Keywords: Lipocalin-2; Brain; Alzheimer disease; Inflammation; Insulin resistance
- MeSH: Alzheimer Disease; Astrocytes; Biological Processes; Bone Marrow; Brain; Cell Movement; Cell Survival; Central Nervous System; Diagnosis; Epithelial Cells; Glycoproteins; In Vitro Techniques; Inflammation; Insulin Resistance; Kidney; Lipocalins; Liver; Microglia; Neurons; Prognosis; Uterus
- From:Clinical Nutrition Research 2018;7(1):1-10
- CountryRepublic of Korea
- Language:English
- Abstract: Lipocalin-2 (LCN2), a secreted glycoprotein belonging to the lipocalin superfamily was reported to participate in various biological processes including cell migration, cell survival, inflammatory responses, and insulin sensitivity. LCN2 is expressed in the multiple tissues such as kidney, liver, uterus, and bone marrow. The receptors for LCN2 were additionally found in microglia, astrocytes, epithelial cells, and neurons, but the role of LCN2 in the central nervous system (CNS) has not been fully understood yet. Recently, in vitro, in vivo, and clinical studies reported the association between LCN2 and the risk of Alzheimer's disease (AD). Here, we reviewed the significant evidences showing that LCN2 contributes to the onset and progression of AD. It may suggest that the manipulation of LCN2 in the CNS would be a crucial target for regulation of the pathogenesis and risk of AD.
